Coronavirus Update: FDA Fast-Tracks Blood Plasma Trials, Novavax Closes In On Vaccine Start
Plus: Japan Accelerates Research As Outbreak Worsens
As US cases set to reach half a million, FDA gives green light to blood plasma trials to help meet urgent need for therapies.
You may also be interested in...
Regulatory authorities have adapted the EU medicines framework to help pharmaceutical companies cope with the consequences of the COVID-19 pandemic.
The entry of India’s state-owned Indian Immunologicals and partner Griffith University in the COVID-19 vaccine race could potentially disrupt pricing dynamics. The alliance is developing a live-attenuated, single dose vaccine, which it hopes will be ready for launch in 18-24 months.
Phase III trial could lead to mid-2020 BLA filing to prevent seasonal influenza in adults 65 and older. Novavax also talked up the potential value of its adjuvant in COVID-19 vaccine development.